*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# CHINA BIOTECH SERVICES HOLDINGS LIMITED
# 中國生物科技服務控股有限公司

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

## VOLUNTARY ANNOUNCEMENT
## THE BNCT DEVICE SUCCESSFULLY PERFORMED ITS FIRST BEAM EMISSION

This voluntary announcement is made by China Biotech Services Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") to inform shareholders of the Company and potential investors of the latest business development of the Group.

The Group's flagship project at the Hainan Boao Lecheng International Medical Tourism Pilot Zone, China, Pengbo (Hainan) BNCT Hospital (the "**Hospital**"), achieved significant progress on 20 November 2025. The NeuCure® neutron irradiation system, the core device for boron neutron capture therapy ("**BNCT**") equipped at the Hospital, successfully performed its first beam emission and has officially entered the final clinical commissioning phase, marking an important milestone in the progression of the project and laying a solid foundation for the future operation of the Hospital.

Leveraging on the supportive policy advantages of the Hainan Boao Lecheng International Medical Tourism Pilot Zone, the system is currently the only BNCT system in the world that has obtained a formal medical device registration certificate and can be directly applied to regular clinical treatment (not in the clinical trial stage). Related clinical treatment services are expected to officially commence in the first quarter of 2026.

The successful beam emission verifies that the various parameters of the core components of the system have met design specifications, marking the formal transition of the project from equipment installation to beam commissioning. This key milestone lays a solid foundation for subsequent core tasks such as precise neutron flux rate control, beam physics verification, and biological effect assessment. It also ensures that the equipment can proceed with clinical treatment to a high standard as planned, providing cancer patients with safe and precise BNCT services.

By order of the Board
**China Biotech Services Holdings Limited**
*Chairman and Executive Director*
**Liu Xiaolin**

Hong Kong, 25 November 2025

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.*